Search Results
33 protocol(s) meet the specified criteria
Phase II Open-Label Single-Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)

101274Not Open *
Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors likely to Express Prolactin Receptor (PRLR)

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

PCCTC c16-168: BRCAAway: Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone plus Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

Phase IB, Open-Label, Dose-Finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Phase II Study of Radium-223 and Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

Phase IB Dose-Escalation Study of Cabozantinib Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104688Not Open *
Cabozantinib plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Nonpharmacologic Interventions for Fatigue in Patients with Cancer

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib in Combination with Physician's Choice of Enzalutamide or Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies

Phase II Study of Optimized Management of NIVOlumab based on REsponse in Patients with Advanced Renal Cell Carcinoma (OMNIVORE Study)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockage in Rare Tumors

Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients with Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-Line Setting (APPEASE)

Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) versus Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: CHAARTED2 Trial

Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)

Phase II, Multicenter, Single-Arm Trial of CV301 in Combination with PD-1/L1 Blockade in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer

Open Label Phase II Study to Evaluate PT2977 for the Treatment of von Hippel Lindau Disease-Associated Renal Cell Carcinoma

[18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone (RROPE) Study: IIT Fluciclovine Prostate

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-Line Chemotherapy in Patients with Metastatic Urothelial Cancer

Phase II Trial of Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)

Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET)

Phase II, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Single-Arm, Multicenter, Phase II Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non-Clear-Cell Renal Cell Carcinoma (nccRCC) who have not Received any Chemotherapy for Advanced Disease

Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations (PROfound)

Open-Label Phase I/IIA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Phase III RandOmized Study Comparing PERioperative Nivolumab versus Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)